| payload |
{"created_at":"2026-04-07T14:22:51.202 {"created_at":"2026-04-07T14:22:51.202355+00:00","signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","url":"https://www.nasdaq.com/articles/corbus-pharma-aligns-fda-registration-path-crb-701-hnscc-and-cervical-cancer","value":{"fp":"271312558886d7dc","kind":"unusual_volume","published_at":"2026-04-07T13:14:27+00:00","source":"Nasdaq Markets","summary":"(RTTNews) - Corbus Pharmaceuticals Holdings, Inc. (CRBP), a clinical-stage company, Tuesday announced that it broadly aligned with the FDA on the registration path for CRB-701, a highly stable Nectin-4 targeting ADC, in head and neck squamous cell carcinoma (HNSCC) and cervical c","tickers":["CRBP","HNSCC"],"title":"Corbus Pharma Aligns With FDA On Registration Path For CRB-701 In HNSCC And Cervical Cancer","url":"https://www.nasdaq.com/articles/corbus-pharma-aligns-fda-registration-path-crb-701-hnscc-and-cervical-cancer"}}... |